AstraZeneca (MEX:AZNN) Cyclically Adjusted Revenue per Share: MXN0.00 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MEX:AZNN AstraZeneca PLC MEX:AZNN
88 GF Score
Price MXN1,628.00
GF Value MXN1,668.53
! 1 Warning Sign
View Full Analysis

What is AstraZeneca Cyclically Adjusted Revenue per Share?

AstraZeneca MEX:AZNN +1.25% 88 Cyclically Adjusted Revenue per Share is MXN0.00 as of Jun. 2026. GuruFocus rates MEX:AZNN with a GF Score™ of 88/100 and a GF Value™ of MXN1,668.53. The stock has 1 warning sign investors should review.

Note: As Cyclically Adjusted Revenue per Share is a main component used to calculate Cyclically Adjusted PS Ratio. If the month end stock price for this stock is zero, result may not be accurate due to the exchange rate between different shares and the data will not be stored into our database. Selected historical data showed in the calculation section below is only for demostration purpose.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

AstraZeneca's adjusted revenue per share for the three months ended in Jun. 2026 was MXN86.576. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is MXN0.00 for the trailing ten years ended in Jun. 2026.

During the past 12 months, AstraZeneca's average Cyclically Adjusted Revenue Growth Rate was 7.90% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 8.40% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 8.90% per year. During the past 10 years, the average Cyclically Adjusted Revenue Growth Rate was 4.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of AstraZeneca was 9.90% per year. The lowest was -0.20% per year. And the median was 5.30% per year.

As of today (2026-07-31), AstraZeneca's current stock price is MXN1628.00. AstraZeneca's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2026 was MXN0.00. AstraZeneca's Cyclically Adjusted PS Ratio of today is .

During the past 13 years, the highest Cyclically Adjusted PS Ratio of AstraZeneca was 6.86. The lowest was 2.82. And the median was 5.33.


AstraZeneca  (MEX:AZNN) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of AstraZeneca was 6.86. The lowest was 2.82. And the median was 5.33.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


AstraZeneca Cyclically Adjusted Revenue per Share Related Terms


AstraZeneca Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for AstraZeneca's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

AstraZeneca Cyclically Adjusted Revenue per Share Chart

AstraZeneca Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 216.29 208.44 204.21 266.28 272.16

AstraZeneca Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 290.18 277.58 272.16 0.00 0.00

MEX:AZNN vs LLY, JNJ, ABBV: Cyclically Adjusted Revenue per Share Comparison

For the Drug Manufacturers - General subindustry, AstraZeneca's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


AstraZeneca Cyclically Adjusted PS Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, AstraZeneca's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where AstraZeneca's Cyclically Adjusted PS Ratio falls into.


MEX:AZNN
88GF Score
AstraZeneca PLC MEX:AZNN
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

AstraZeneca Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, AstraZeneca's adjusted Revenue per Share data for the three months ended in Jun. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=86.576/142.1000*142.1000
=86.576

Current CPI (Jun. 2026) = 142.1000.

AstraZeneca Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201609 43.520 101.500 60.928
201612 45.476 102.200 63.230
201703 40.194 102.700 55.614
201706 36.059 103.500 49.507
201709 44.632 104.300 60.807
201712 44.668 105.000 60.451
201803 37.124 105.100 50.193
201806 39.974 105.900 53.638
201809 39.418 106.600 52.545
201812 49.723 107.100 65.972
201903 42.001 107.000 55.779
201906 42.627 107.900 56.138
201909 48.196 108.400 63.179
201912 47.861 108.500 62.682
202003 56.736 108.600 74.237
202006 55.156 108.800 72.037
202009 55.379 109.200 72.064
202012 56.131 109.400 72.909
202103 56.720 109.700 73.472
202106 62.074 111.400 79.181
202109 67.802 112.400 85.718
202112 78.871 114.700 97.712
202203 72.641 116.500 88.603
202206 69.452 120.500 81.901
202209 70.848 122.300 82.318
202212 70.029 125.300 79.418
202303 62.851 126.800 70.435
202306 62.729 129.400 68.886
202309 64.160 130.100 70.078
202312 65.374 130.500 71.185
202403 67.444 131.600 72.825
202406 75.970 133.000 81.168
202409 85.499 133.500 91.007
202412 99.412 135.100 104.563
202503 89.041 136.100 92.966
202506 87.304 138.400 89.638
202509 89.259 138.900 91.315
202512 90.031 139.900 91.447
202603 88.914 140.800 89.735
202606 86.576 142.100 86.576

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of MXN0.00 mean?
AstraZeneca (MEX:AZNN) has a Cyclically Adjusted Revenue per Share of MXN0.00 as of Jun. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on AstraZeneca and its competitors.
Is AstraZeneca's Cyclically Adjusted Revenue per Share too high?
AstraZeneca's current Cyclically Adjusted Revenue per Share is MXN0.00. Overall, AstraZeneca has a GF Score™ of 88/100, reflecting its overall financial health beyond just this single metric.
How does AstraZeneca's Cyclically Adjusted Revenue per Share compare to LLY and JNJ?
AstraZeneca's Cyclically Adjusted Revenue per Share of MXN0.00 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Drug Manufacturers company?
A good Cyclically Adjusted Revenue per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on AstraZeneca and its competitors. AstraZeneca's current Cyclically Adjusted Revenue per Share is MXN0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AstraZeneca stock overvalued right now?
AstraZeneca (MEX:AZNN) has a current Cyclically Adjusted Revenue per Share of MXN0.00. The stock's GF Value™ is MXN1,668.53, compared to a current price of MXN1,628.00 — trading 2.4% below its estimated fair value. The current Cyclically Adjusted Revenue per Share is MXN0.00. AstraZeneca's overall GF Score™ is 88/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For AstraZeneca (MEX:AZNN), the current Cyclically Adjusted Revenue per Share is MXN0.00 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is AstraZeneca (MEX:AZNN) Overvalued in 2026?

Based on GuruFocus' analysis, AstraZeneca stock appears to be undervalued. The current stock price of MXN1,628.00 is trading 2.4% below its estimated GF Value™ of MXN1,668.53.

Key valuation signals for MEX:AZNN:

  • Cyclically Adjusted Revenue per Share: MXN0.00
  • GF Value™: MXN1,668.53 vs. price of MXN1,628.00 (2.4% below fair value)
  • GF Score™: 88/100 with 1 warning sign

No single metric tells the full story. See the MEX:AZNN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


AstraZeneca Business Description

Address 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, GBR, CB2 0AA
A merger between Astra of Sweden and Zeneca of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (over 40% of total revenue), cardiovascular, renal, and metabolic (over 20%), rare disease (16%), and respiratory and immunology (15%). The majority of sales comes from international markets, with the United States representing close to one-third of its sales.
88GF Score

Get the complete analysis for MEX:AZNN

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN1,628.00
Price
MXN1,668.53
GF Value